Apostle MiniMax technology has been used and cited in this study:
- Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Casazza JP, Cale EM, et al. the VRC603 Study Team. Nature Medicine April 11, 2022
- Download PDF
